GUIDANCE DOCUMENT
CVM GFI #49 Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis December 2024
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-1993-D-0285
- Issued by:
-
Guidance Issuing OfficeCenter for Veterinary Medicine
This guidance provides target animal safety and effectiveness study design considerations and recommendations for sponsors of bovine mastitis drug products with antibacterial activity that are administered by intramammary infusion. This guidance replaces the original guidance for industry (GFI) #49, issued in April 1996, entitled “Target Animal Safety and Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow Products).” Sponsors may propose alternatives, with appropriate justification, to the study designs described in this guidance. CVM encourages sponsors to meet with us early in their investigational product development timeline to propose and agree on the appropriate study designs for their specific project.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-1993-D-0285.
Questions?
- Paulette Salmon
- Center for Veterinary Medicine
Food and Drug Administration
7500 Standish Place, HFV-133
Rockville, MD 20855
- pauline.salmon@fda.hhs.gov
- 240-402-6556